Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Pre-Surgery boost help cancer patients recover faster?

NCT ID NCT06275737

Symptom relief Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study tests an 8-week program of nutrition advice, exercise, and psychological support for people with pancreatic or esophageal cancer before they have surgery. The goal is to see if patients can complete the program and if it helps them prepare for surgery. Only 9 patients are enrolled, so this is a very early look at whether this approach is feasible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prehabilitation program (nutritional, psychological, and personalized physical activity interventions)
What this could lead to
If successful, this program could help patients feel stronger and recover better after surgery for pancreatic or esophageal cancer.
What could go wrong
This is a very small, early feasibility study with only 9 participants, so results may not apply to everyone. The program requires significant effort and may not be suitable for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed and dated patient informed consent form (ICF) and willingness to comply with all study procedures and availability for the study duration, 2. Histologically or cytologically proven, localized PDAC or OGC, 3. Indication to a neoadjuvant treatment with triplet chemotherapy for ≥ 4 cycles (8 weeks) validated by the multidisciplinary board, Note: Patient treated for PDAC, dose reduction of oxaliplatin or irinotecan is authorized. 4. Age \> 18 years; If aged ≥ 75 years: G8 score must be ≥ 14 and if \< 14 validation of oncogeriatric specialist, 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 at the inclusion visit, 6. No prior treatment for PDAC or OGC before starting chemotherapy (FLOT or FOLFIRINOX), 7. At least one measurable or evaluable lesion as assessed by Computerized Tomography scan or Magnetic resonance imaging according to RECIST 1.1 and feasibility of repeated radiological assessments, 8. Adequate hematologic and end-organ function allowing the triple combination chemotherapy protocol, 9. Registration in a national health care system (PUMa - Protection Universelle Maladie included). Exclusion Criteria: 1. Evidence of metastatic disease at imaging (validated in multidisciplinary team evaluation), 2. Histology of other than adenocarcinoma, 3. Any medical (including cardiovascular, respiratory, psychiatric, musculoskeletal, or neurological) condition contra-indicating exercise practice, 4. Patients with medical contraindication to surgery due to general condition or comorbidities 5. Pregnancy or breast-feeding, 6. Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent,

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms gastroesophageal cancer pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer Pancreatic ductal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CENTRE HOSPITALIER UNIVERSITAIRE ROUEN - CHU Charles Nicolle

    NOT_YET_RECRUITING

    Rouen, France

  • CHU de Reims

    NOT_YET_RECRUITING

    Reims, France

  • Centre Hospitalier Universitaire Dijon Bourgogne

    NOT_YET_RECRUITING

    Dijon, France

  • Centre Hospitalier Universitaire Tours - Hopital Trousseau

    NOT_YET_RECRUITING

    Tours, France

  • Centre Hospitalier Universitaire de Lille

    NOT_YET_RECRUITING

    Lille, France

  • Groupe hospitalier Rance Emeraude (CHU Saint-Malo)

    NOT_YET_RECRUITING

    St-Malo, France

  • Hospital La Timone

    NOT_YET_RECRUITING

    Marseille, France

  • INSTITUT CURIE de SAint Cloud

    RECRUITING

    Saint-Cloud, France

  • Institut Daniel Hollard - Groupe Hospitalier Mutualiste de Grenoble

    NOT_YET_RECRUITING

    Grenoble, France

  • Institut Paoli-Calmettes

    NOT_YET_RECRUITING

    Marseille, France

  • Institut de Cancerologie de L'Ouest Rene Gauducheau

    NOT_YET_RECRUITING

    Saint-Herblain, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.